Xiling Lab

Xiling Lab, established in August 2016 in Chengdu, China, is a biopharmaceutical company concentrated on developing and producing active pharmaceutical ingredients (APIs) and finished drug formulations. The company was co-founded by Dr. Jinkun Huang, who serves as CEO, and Dr. Dejian Xie, the Chief Operating Officer. Xiling Lab operates with a business model that encompasses both the development of high-end generic drugs and the discovery of original, innovative therapeutics, primarily for the oncology market.

The company's revenue generation is rooted in the production and sale of complex generic drugs and APIs, alongside strategic partnerships and out-licensing agreements for its products. It serves a global market, with sales in East Asia, Europe, North America, South America, and the Middle East. A core component of its strategy is its XL-XDC® technology platform, which is instrumental in the creation of antibody-drug conjugates (ADCs) for cancer treatment. This platform utilizes a variety of drug payloads and proprietary SuperHydra® Linkers designed to improve the stability and delivery of the therapeutics. Key products in its pipeline include generic versions of anti-tumor drugs like Eribulin, Lurbinectedin, and Trabectedin, as well as iodine-based contrast agents.

Significant milestones for Xiling Lab include securing its angel round of financing in March 2017, followed by multiple subsequent funding rounds, including a $13.9M Later Stage VC round in November 2022, contributing to a total of $37.8M raised. The company has achieved key regulatory approvals, such as passing site verification by China's Center for Food and Drug Inspection (CFDI) for two of its projects in late 2021. In February 2023, it received its "Drug Production License" and submitted an application for its first self-owned product, Eribulin mesylate injection. The company's premier ADC candidate, SMP-656, which targets HER2, has advanced to Phase 1 clinical trials, marking a critical step in its innovative drug development efforts.

Keywords: biopharmaceutical, active pharmaceutical ingredients, API manufacturing, generic drugs, oncology therapeutics, antibody-drug conjugates, ADC technology, cancer treatment, drug discovery, XL-XDC platform, Eribulin, Lurbinectedin, contrast agents, pharmaceutical development, clinical trials, Jinkun Huang, Dejian Xie, Chengdu, drug formulation, out-licensing